The European Commission announced on Tuesday 19 July that the European Health Emergency Preparedness and Response Authority (HERA) had signed a joint procurement framework contract for the supply of the antiviral treatment Veklury, developed by the firm Gilead.
Veklury contains the active substance remdesivir, a viral RNA polymerase inhibitor. The framework agreement provides for the possibility for the 22 States that have chosen to participate in this agreement to purchase up to 2,250,000...